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Abstract
Background: It is difficult to keep control over prescribing behaviour in general practices. The purpose
of this study was to assess the effects of a dissemination strategy of multidisciplinary guidelines on the
volume of drug prescribing.
Methods: The study included two designs, a quasi-experimental pre/post study with concurrent control
group and a random sample of GPs within the intervention group. The intervention area with 53 GPs was
compared with a control group of 54 randomly selected GPs in the south and centre of the Netherlands.
Additionally, a randomisation was executed in the intervention group to create two arms with 27 GPs who
were more intensively involved in the development of the guideline and 26 GPs in the control group.
A multidisciplinary committee developed prescription guidelines. Subsequently these guidelines were
disseminated to all GPs in the intervention region. Additional effects were studied in the subgroup trial in
which GPs were invited to be more intensively involved in the guideline development procedure. The
guidelines contained 14 recommendations on antibiotics, asthma/COPD drugs and cholesterol drugs
The main outcome measures were prescription data of a three-year period (one year before and 2 years
after guideline dissemination) and proportion of change according to recommendations.
Results: Significant short-term improvements were seen for one recommendation: mupirocin. Long-term
changes were found for cholesterol drug prescriptions. No additional changes were seen for the
randomised controlled study in the subgroup. GPs did not take up the invitation for involvement.
Conclusion: Disseminating multidisciplinary guidelines that were developed within a region, has no clear
effect on prescribing behaviour even though GPs and specialists were involved more intensively in their
development. Apparently, more effort is needed to bring about change.
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Background
Health care expenditure in the Netherlands increases each
year, as it does in other European countries. Drug pre-
scribing is an important contributor to this increase in
costs, and these costs are expected to continue to increase
relevantly in the coming years [1-3]. Medication is not
always prescribed effectively: drugs may be prescribed
unnecessarily and lower-cost alternatives are not always
taken into consideration. The problem can be attributed
to demographic factors (growth and ageing of the popula-
tion), the trend towards new but usually more expensive
drugs, patients' increased awareness, pressure from the
industry, and last but not least the differences in prescrib-
ing practices between primary and secondary care ori-
ented physicians [4,5]. Physicians are also known to
prescribe more easily as a result of today's high level of
work-related stress and routines [6].
Clinical guidelines may induce small improvements, both
in processes and in the outcomes of care [7]. Simple top-
down dissemination of mono-disciplinary guidelines
alone is not effective [8-12]. To bring about change, a
more powerful strategy could be multidisciplinary guide-
lines and probably even more so if key regional represent-
atives from primary and secondary care are involved in the
development. Implementation experts indicate that
multistage involvement in the development of a guideline
can be a positive contributor to effective implementation
of guidelines [13,14]. If national guidelines are involved,
adjusting them to the local situation and to specified
needs experienced in the target group increases commit-
ment [15,16]. We have therefore adopted an intensive
guideline development procedure, involving local repre-
sentatives of the relevant medical disciplines [17,18].
The intensity is related to the time and energy that was put
into the strategy of guideline development to create sup-
port among GPs. We set up a study in which we assessed
the effects of our intensive multistage guideline develop-
ment. We hypothesised that this strategy could lead to a
modest but relevant change of volumes of prescriptions in
the desired direction. As we used two comparisons, we
were able to study the effects of dissemination separately
from the effects of involving the target group in the prep-
aration and development of the guidelines.
Methods
Design and population
A quasi-experimental study (a pre/post study with a con-
current control group) was executed (fig. 1). Since we had
an enormous amount of data from the insurance compa-
nies at our disposal (about 700 GPs in the centre and
south of the Netherlands), it was practically impossible to
include them all. The Maastricht region (intervention
region, n = 53 GPs) was compared with a random sample
of 54 GPs drawn from the remaining GPs (control group).
First, however, an randomised controlled trial (RCT) was
carried out within the intervention group; 27 GPs were
invited for a more intense role in the development proce-
dure and were compared with 26 GPs in a corresponding
control group. The inclusion criteria were: completeness
of the GPs' data (no missing data per GP for more than
one year) and at least 500 patients in the GPs' practice. As
the two groups in the RCT turned out to be comparable,
we executed the second comparison: we compared the
entire Maastricht region with an external control group,
selected at random from all the available data. A pre trial
power-calculation was not performed; the study con-
cerned a pragmatic trial, where evaluation was planned
alongside an intervention being executed anyway. For this
study, only GPs who were not already participating in
another regional intervention of similar character, were
sent the guideline by post and invited to give comments
(n = 53 GPs). The GPs in both designs were not aware of
the fact that they were in an evaluation study, because
only anonymous volume data were collected from an
existing database. There was therefore no need for GPs or
patients to give informed consent. The asthma/COPD and
cholesterol guidelines were disseminated in March 2002.
Baseline data were gathered one year before, and follow-
up measurements were made one and two years after the
dissemination of each guideline.
Strategy
The guideline topics were chosen by the steering commit-
tee, existing of decision-making representatives (pharma-
cists, GPs, hospital staff and regional insurance
company). Clinical importance in primary care (common
problems) and expected health gains were the main crite-
ria in prioritisation. The first multidisciplinary guideline
was developed for antibiotics, because non-rational atti-
tudes towards prescriptions and an increase of resistance
in micro-organisms have been observed. Over 50% of the
antibiotics prescriptions for respiratory tract problems are
not used appropriately [19,20]. Guidelines for asthma,
COPD and cholesterol have also been developed, due to
the high prevalence of these diseases in the population
and the corresponding high costs [21]. The guidelines
were actually developed by independent multidiscipli-
nary expert teams that included community pharmacists,
specialists, GPs and a hospital pharmacist, and were based
on Dutch national guidelines, practical experience and
consensus. The participating GPs were not involved in the
trial.
After the development, we used different methods to val-
idate the conceptual guidelines. For the guideline on anti-
biotics we started with visiting PTAMs in the region to get
comments on the conceptual guidelines and create
involvement. For the guidelines on asthma, COPD andBMC Health Services Research 2006, 6:145 http://www.biomedcentral.com/1472-6963/6/145
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cholesterol, the conceptual guidelines were sent by post to
a random sample of GPs within the intervention group,
and those GPs were asked to comment and encouraged to
do so. The guideline committee stressed the importance of
knowing the GPs' comments, and that the comments
would be taken very seriously in finalising the guideline.
Due to the low response rate and based on the expertise of
the expert teams, a number of key individual GPs were
also contacted in a more active way to generate com-
ments. The guidelines were finalised by presenting the
GPs comments to the multidisciplinary expert teams. The
Integrated Care Unit of the University Hospital of Maas-
tricht provided both the expertise and the facilitating con-
ditions to disseminate the guidelines within the region.
All the GPs in the intervention group received the final-
ised paper guidelines in a ring binder by post. The antibi-
otics guideline was sent out in 2001 and the asthma,
COPD and cholesterol guidelines were forwarded in
2002.
Data collection and analysis
Data were supplied by the two largest insurance compa-
nies in the region, which implied that about 70 percent of
the total population in the region was covered.
Prescription data were gathered retrospectively per GP per
month during the period 2001–2004. Expected directions
of change have been defined based on the detailed recom-
mendations contained in the guidelines, in combination
with estimates based on the expertise of the initially
involved key regional representatives. The drugs that were
selected and the desired directions of change are listed in
tables 1 and 2, in the first and second columns.
The effect of the strategy and the differences in the pre/
post changes between groups were tested with unpaired
Student's t-tests and Mann Whitney tests using SPSS
12.0.1 software. Short-term effects were calculated one
year after the dissemination of the guidelines, and long-
term effects two years after. We set our alpha conserva-
tively at 0.01 because of the multiple testing.
Flowchart of research population and randomised trial in subgroup Figure 1
Flowchart of research population and randomised trial in subgroup.B
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Table 1: Mean total number of drug prescriptions per GP per year, standardised per 1000 enlisted patients for the total intervention region versus a matched control group
Desired direction of drug pre Short term Δ short term Long term Δ Long term
I (n = 53) C (n = 54) I (n = 53) C (n = 54) I (n = 53) C (n = 54) I (n = 53) C (n = 54) I (n = 53) C (n = 54)
Drug indicators
Antibiotics2 ↓ 639 (551,833) 491 (388,595) 667 (532,812) 489 (386,601) 3 (-56,70) 1 (-30,40) 652 (512,767) 486 (405,602) -20 (-91,65) -6 (-40,43)
Chinolones2 ↓↓ 37 (22,53) 24 (13,34) 36 (23,48) 22 (12,33) 1 (-12,9) 1 (-6,5) 34(27,44) 21 (14,31) -4 (-10,4) -1 (-7,5)
Nitrofurantoin1 ↑ 26 (19,33) 33 (27,39) 27 (22,33) 33 (26,40) 1 (-4,6) 0 (-3,3) 31(25,37) 37 (30,43) 5 (-1,10) 4 (0,8)
Trimethoprim1 ↑ 27 (20,33) 24 (18,30) 29 (21,36) 24 (18,29) 2 (-2,6) -1 (-3,2) 26(20,32) 22 (17,28) -1 (-6,5) -2 (-6,2)
Amoxicillin with clav.acid2 ↓ 31 (24,51) 27 (18,41) 31 (19,46) 26 (17,41) -3 (-10,8) -1 (-8,5) 28(18,45) 28 (19,37) -2 (-16,11) 0 (-10,5)
Amoxicillin2 ↓ 76 (48,126) 62 (37,94) 69 (34,112) 67 (44,100) -6 (-53,20) -1 (-12,8) 54(38,104) 58 (37,109) -14 (-35,2) -2 (-17,13)
Doxycyclin1 ↓ 133 (109,156) 83 (71,95) 126 (104,148) 79 (68,90) -7 (-20,6) -4 (-10,2) 114(93,135) 73 (62,84) -19 (-35, -3) -10 (-16, -4)
Mupirocin2 ↓ 5 (2,20) 5 (1,10) 5 (2,13) 5 (1,16) -1 (-6,1) 1 (-2,5)* 5(2,11) 3 (1,12) 0 (-6,2) 0 (-3,2)
Cholesterol synthesis inhibitors (Statins)1 ↑↑ 182 (154,209) 140 (115,164) 219 (188,249) 162 (136,189) 37 (28,46) 22 (16,29) 294 (248,339) 194 (164,224) 112 (87,137) 54 (41,66)*
Asthma & COPD
Long-term beta2-sympaticomimetics1 ↑ 40 (33,46) 40 (32,47) 37 (31,43) 37 (30,44) -3 (-6, -1) -3 (-6,0) 36(29,42) 31 (25,38) -4 (-8,0) -8 (-13, -4)
Asthma
Short-term beta2-sympaticomimetics2 ↓ 28 (21,44) 29 (19,35) 29 (18,39) 28 (19,41) 0 (-6,6) 2 (-3,7) 28(19,36) 27 (20,38) -4 (-8,1) -1 (-8,5)
Inhaled corticosteroids2 ↑ 21 (14,33) 19 (13,28) 19 (10,28) 21 (13,33) -3 (-8,0) -1 (-5,4) 14(9,23) 18 (11,26) -7 (-11, -2) -2 (-10,1)
COPD
Short-term beta2-sympaticomimetics1 - 62 (54,70) 42 (34,49) 61 (52,70) 42 (34,49) -2 (-6,3) 0 (-3,4) 59(50,69) 36(29,42) -3(-8,2) -6 (-10, -2)
Inhaled corticosteroids1 ↓ 55 (46,64) 51 (42,59) 51 (42,60) 48 (39,57) -5 (-8, -1) -3 (-6,1) 41(33,48) 40(32,48) -15(-20, -10) -10 (-15, -6)
1. Mean (CI) for normally distributed variables
2. Median (P25-P75 intervals) for skewed variables
* T-test unpaired/Mann-Whitney p < 0.01B
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Table 2: Mean total number of drug prescriptions per GP per year, standardised per 1000 enlisted patients for the randomised more intensively involved group in the intervention region 
versus a matched control group
Desired direction of drug pre Short term Δ short term Long term Δ Long term
I (n = 27) C (n = 26) I (n = 27) C (n = 23) I (n = 27) C (n = 26) I (n = 27) C (n = 26) I (n = 27) C (n = 26)
Drug indicators
Antibiotics2 ↓ 611 (536,833) 530 (421,665) 643 (413,812) 524 (443,622) 6 (-43,82) 3 (-48,38) 661 (435–734) 526 (418,649) 11 (-92,73) -7 (-61,47)
Chinolones2 ↓↓ 34 (18,51) 25 (14,36) 27 (12,47) 24 (12,32) 3 (-12,8) -2 (-8,2) 30 (21,38) 19 (17,33) -3 (-11,3) -1 (-7,5)
Nitrofurantoin1 ↑ 23 (15,31) 31 (21,40) 27 (20,35) 31 (21,42) 4 (-3,12) 1 (-3,5) 32 (24,41) 36 (26,46) 9 (1,18) 6 (0,11)
Trimethoprim1 ↑ 32 (22,41) 29 (19,38) 32 (20,44) 28 (20,37) 1 (-6,7) 0 (-4,3) 26 (18,35) 23 (16,31) -5 (-13,3) -5 (-11,0)
Amoxicillin with clav.acid2 ↓ 33 (22,68) 28 (16,43) 41 (16,67) 26 (17,45) 5 (-9,19) -2 (-8,5) 23 (16,64) 30 (21,37) -3 (-16,10) 3 (-8,10)
Amoxicillin1 ↓ 92 (59,125) 104 (63,145) 57 (37,76) 98 (62,135) -36 (-75,4) -5 (-16,6) 78 (37,119) 96 (65,128) -14 (-36,8) -7 (-25,10)
Doxycyclin1 ↓ 125 (89,160) 89 (73,105) 113 (82,144) 86 (71,100) -12 (-37,14) -4 (-12,5) 103 (74,132) 81 (69,93) -22 (-52,8) -8 (-16,0)
Mupirocin1 ↓ 12 (5,20) 7 (4,9) 10 (3,16) 6 (3,9) -3 (-5,0) -1 (-3,2) 8 (4,12) 6 (3,8) -5 (-9,0) -1 (-3,1)
Cholesterol synthesis inhibitors 
(Statins)1
↑↑ 150 (119,182) 139 (109,170) 182 (144,220) 166 (129,203) 32 (20,43) 27 (17,36) 229 (185,273) 194 (153,235) 79 (60,98) 55 (35,75)
Asthma & COPD
Long-term beta2-sympaticomimetics1 ↑ 35 (27,44) 36 (28,43) 34 (25,42) 33 (25,41) -2 (-5,2) -2 (-7,2) 32 (23,42) 28 (21,35) -3 (-8,3) -8 (-14, -2)
Asthma
Short-term beta2-sympaticomimetics1 ↓ 37 (26,48) 35 (23,47) 37 (26,48) 37 (25,49) 0 (-4,4) 2 (-1,6) 34 (24,44) 36 (24,48) -3 (-8,2) 1 (-4,6)
Inhaled corticosteroids2 ↑ 24 (16,35) 24 (13,28) 22 (12,32) 21 (12,33) -5 (-8,0) -1 (-5,5) 15 (10,29) 19 (13,28) -9 (-11, -4) 1 (-7,1)*
COPD
Short-term beta2-sympaticomimetics1 - 65 (51,79) 38 (29,47) 63 (48,79) 39 (29,48) -2 (-9,6) 1 (-4,5) 61 (45,77) 32 (25,40) -4 (-12,5) -5 (-12,1)
Inhaled corticosteroids1 ↓ 59 (45,74) 48 (37,59) 55 (40,70) 46 (34,60) -5 (-10,1) -2 (-7,3) 41 (29,53) 39 (28,50) -18 (-26, -11) -9 (-16, -2)
1. Mean (CI) for normally distributed variables
2 Median (P25-P75 intervals) for skewed variables
* T-test unpaired/Mann-Whitney p < 0.01BMC Health Services Research 2006, 6:145 http://www.biomedcentral.com/1472-6963/6/145
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Results
As far as we can ascertain, the GPs in the two groups did
not differ on the main characteristics. The mean age of
male GPs in the intervention group was 50.0 years and
53.3 in the control group. The mean age of the female GPs
in the intervention group was 48.8 years and 45.5 in the
control group. Overall, the percentage of male GPs was
only slightly different in both groups: in the intervention
group, 85%(45) of the GPs were male, as compared with
76%(41) in the control group. Table 1 presents the mean
total number of drug prescriptions per GP per year, stand-
ardised per 1000 enlisted patients over a baseline meas-
urement (2001 or 2002), the short-term effects (one year)
and long-term effects (two years). Table 1 also presents
the absolute changes in the short term and long term per
1000 enlisted patients per GP. Table 2 presents the same
data for the random sample of GPs who were invited for
a more intense role in the development procedure.
Less than 10% of the GPs that were invited to play a
greater role actually commented on the conceptual guide-
lines. The exact number varied according to the specific
guideline. Most of the comments did not relate to content,
but rather concerned questions about the development
procedure.
For the guideline dissemination (quasi experiment),
results show that a significant change in the desired direc-
tion was found for one specific antibiotic (mupirocin): a
reduction of one prescription per 1000 patients compared
to an increase of one (p = 0.0014) in the short term. No
significant effect was seen for other antibiotics, either in
the short term or the long term. For cholesterol, signifi-
cant long-term effects were found; an increase of 112 pre-
scriptions per 1000 patients in the intervention group
compared to an increase of 54 in the control group (p <
0.0001). No significant effect was seen in the short term
or long term for any asthma and COPD drugs.
For antibiotics and cholesterol, no additional effects were
found in the randomised study of GPs with a greater
involvement (table 2). For asthma and COPD drugs, sig-
nificant changes were found in the control group instead
of the intervention group. Instead of the desired increase,
we found a decrease of 9 prescriptions per 1000 patients
in the intervention group compared with a decrease of
one prescription in the control group for inhaled corticos-
teroids for asthma (p = 0.0099).
Discussion
We found no clear impact of disseminating the rigorously
developed multidisciplinary guidelines on the prescribing
performance of GPs. A significant effect was found for two
drugs: mupirocin and cholesterol lowering drugs. The
change in mupirocin however does not seem very rele-
vant, because it is rarely prescribed and by and large pre-
scribed for minor ailments. The long-term effect for
cholesterol lowering drugs is interesting. The standard
deviation of prescribing drugs per GP turned out to be
unexpectedly large. Although no significant effects were
seen for the other drugs, only small changes can be seen
on other indicators. The invitation for GPs to be involved
in the development procedure caused no desirable effects
in the subgroup.
There are some issues for consideration. First, although
unlikely the quasi-experimental design cannot guarantee
that the observed changes are the result of the strategy. It
is possible that the effects found were caused by coinci-
dence or by an unknown non-specific factor. Although the
intervention group in both designs seems to be higher in
volumes of prescription at baseline, both groups seem
comparable in the exposure to quality improvement strat-
egies that have been performed otherwise in the region. A
second issue for consideration is the pragmatic base of the
trial in which two regions were compared. This has caused
a restriction in the number of GPs in the trial. We were not
in the position to improve this. Together with the rela-
tively high variation among the primary variable (vol-
umes of prescription per GP per 1000 patients per year)
the power of the study was negatively influenced. Another
power calculation executed after ending the study, based
on the large standard deviations and the number of GPs,
showed that this resulted in a power of 40%. In this study
only large differences could be detected. We found a few
significant results, although the significant effect of mupi-
rocin is not so interesting because mupirocin is rarely pre-
scribed and the disease is a minor ailment. Given the fact
that this study was no selected sample and the participat-
ing GPs were a fine representation for the Dutch GPs other
results are not expected in larger trials. Besides, when eval-
uating this intervention in an economic study we wonder
if the changes in prescribing behaviour are in balance to
such huge efforts made in investment and implementa-
tion costs.
Only volume data of prescriptions were used in this initial
stage of the study. These figures are therefore not linked to
any diagnosis. However, some drugs are prescribed for
several different medical problems, while the guideline
may contain opposing prescription recommendations.
For example, amoxicillin is recommended for the treat-
ment of bronchitis and otitis media acuta, whereas amox-
icillin is discouraged in cases of acute cystitis. On the one
hand, for statin use, there is a situation of overuse for
patients with low risk on cardiovascular disease; on the
other hand, there is a situation of underuse for high-risk
patients like diabetes patients [21]. It is therefore possible
that the results are somewhat underestimated in the sense
that possible results were kept hidden. Additional infor-BMC Health Services Research 2006, 6:145 http://www.biomedcentral.com/1472-6963/6/145
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mation about diagnosis and cholesterol rates would be
needed to make a more precise analysis.
A strong aspect of our study is that long-term effects were
measured. For statin-prescription, the initial non-signifi-
cant effect appeared to be significant at the long run. A
positive factor that may have contributed to an increased
willingness to follow the cholesterol medication guideline
is that our strategy concerns guidelines that have been for-
mulated by representatives from all disciplines and was
intended to improve prescription behaviour in both pri-
mary care physicians ánd medical specialists.
Overall, the implementation strategy only generated lim-
ited results. Implementation experts indicate that if guide-
lines are developed by the clinicians who are to use them
this will be a positive contributor to the effect of guide-
lines. Achieving consensus on draft guidelines and creat-
ing a sense of 'ownership' through a process of
development on several levels (central, local and individ-
ual) is essential for successful implementation of guide-
lines [22,23]. We have paid specific attention to this
aspect, firstly by involving representatives from all disci-
plines in the development of the guidelines. The term
intensity is therefore related to the time and energy that
was put into the guideline development strategy to create
support among GPs. Secondly, we also focused specifi-
cally on the doctors' acceptance of the guidelines by
including them in the validation procedure. It is not clear
why the GPs did not respond to the invitation for com-
ment. Possibly, we were successful in choosing opinion
leaders to such extent that GPs did not see the need to
comment on guidelines that were prepared by GPs they
trusted. A second explanation lies in the assumption that
the invitation by mail did not work: only a few GPs
responded to the invitation to comment on the guideline.
GPs might have had comments but did not think this
would have any impact in the final guideline. In short, we
did not succeed in getting GPs involved locally in the val-
idation procedure. Apparently this way of getting GPs
involved is not appropriate and possibly explains why the
effect was only limited.
To create involvement in the validation procedure we
searched for a successful method to achieve this. During
the validation of the antibiotics guideline we started with
visiting PTAMs in the region to get comments on the con-
ceptual guidelines and create involvement. This turned
out to be very time consuming and caused much delay in
the dissemination of the final guideline. Therefore, during
the validation of the asthma and the COPD guideline we
chose for a less labour-intensive method by asking GPs to
comment by mail. After finishing the analyses for this
study, we subsequently started (not included in the data
of the manuscript) with inviting GPs to feedback meet-
ings. The results of this method were more convincing. We
highly recommend the feedback meetings to be an effec-
tive method to create involvement among GPs during the
validation procedure.
To obtain a more solid or extensive effect, an additional
implementation strategy is desired. Feedback and remind-
ers could be an necessary strategy to change GPs behav-
iour [24-26]. For example, a computerised decision
support system could give feedback to a doctor as soon as
the prescription behaviour differs from the behaviour rec-
ommended in the guideline. As long as the doctor does
not deviate from the guideline, the system will not inter-
fere with the primary care physicians' information system,
and the doctor giving the prescription will not be inter-
rupted by the feedback system.
We did not perform an economic evaluation by relating
the (change in) costs of prescription to the costs of the
interventions (guideline development and dissemina-
tion) [27,28]. If we were to choose to compare the total
expenses of the intensive development procedure of all
guidelines with the cost savings, we would expect all the
findings to be negative, because the strategy was time and
energy consuming and its impact was only moderate.
Before aiming to intensify the development procedure of
guidelines, the costs and savings of such a strategy need to
be investigated thoroughly and executed when the pro-
ceeds of the intervention outweighs the costs of it [29,30].
Conclusion
Disseminating multidisciplinary guidelines that were
developed within a region, has no clear effect on prescrib-
ing behaviour even though GPs and specialists were
involved more intensively in their development. Appar-
ently, more effort is needed to bring about change.
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